Darnytsia Expands Its Geography: A New Antifungal Medicine Registered in Bosnia and Herzegovina

Darnytsia Pharmaceutical Company has officially registered a new antifungal medicinal product for systemic therapy and prevention of fungal infections in Bosnia and Herzegovina. The company's motto —safety and efficacy for every patient— is continually confirmed on the international stage.

The antifungal medicine is used to treat infections caused by yeast and other pathogenic fungi, including candidiasis (skin, mucous membranes, internal organs), cryptococcosis, skin and nail mycoses, as well as prevention in patients with weakened immunity or those undergoing prolonged antibiotic therapy. The product shows proven efficacy and an appropriate safety profile, as confirmed by international quality control standards.

Registration in Bosnia and Herzegovina became possible due to compliance with the strictest requirements of regulatory authorities, which are closely aligned with European standards. This once again demonstrates that Ukrainian pharmaceuticals are competitive on a global level.

"With each new international success, we prove that the quality and reliability of Ukrainian medicines are not just an ambition, but a daily reality. When our products earn the trust of foreign markets, it motivates us to confidently enter new markets and make innovative medicine accessible to patients worldwide," notes Anna Pavliuk-Havrylova, Head of International Registration and New Market Entry at Darnytsia Pharmaceutical Company.

Darnytsia is steadily expanding its presence in international markets: the company’s products are already available in over 20 countries around the world.